Anlon Healthcare Ltd IPO

The company is subject to stringent quality specifications and regular customer audits. Non-compliance may result in order cancellations, warranty claims, or reputational damage. In the past, its manufacturing facility was non-operational for a period of four (4) months to address certain directions and recommendations issued by the Brazilian Health Regulatory Agency, which temporarily halted the company manufacturing operations.

Any failure to maintain product quality or comply with evolving quality standards may lead to customer dissatisfaction, loss of business, and legal liability.

The company has a limited operating history in manufacturing.

In the past, the company Manufacturing Facility remained non-operational for a period of four (4) months, resulting in a halt in its manufacturing capabilities. Any future event that causes a temporary or prolonged shutdown of the company Manufacturing Facility could significantly impact its production capacity, disrupt the copmpany supply chain, and adversely affect its business operations.

The Company is yet to place orders for the equipment, plant and machinery for the expansion of the Manufacturing Facility. Any delay in placing orders or procurement of such equipment, plant and machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.

The company is products are exposed to risks of contamination, adulteration, and tampering during manufacturing, storage, or transit, which may adversely impact product quality, lead to regulatory non-compliance, and result in reputational and financial loss.

The company exposed to risks of product recalls and liability claims, which may involve significant costs, reputational harm, and regulatory consequences.

Its revenue from operations is dependent upon a limited number of customers and the loss of any of these customers or loss of revenue from any of these customers could have a material adverse effect on the company business, financial condition, results of operations and cash flows.

Its derive majority of the company revenue from the sale of its products to various segments of pharmaceutical Industry and any reduction in demand for the company customer products, or if such products become obsolete due to a breakthrough in the development of alternate drugs, could have an adverse effect on the company business.

Comparison of the comapny valuation multiples with peer companies may highlight potential investment risks.